Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.42 |
| ▸ | TP53 | P04637 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15034146 | 0.94 | MAPT (0.39) | MAPTTP53POLBSMN1; SMN2GRM5 | |
| SCHEMBL15020006 | 0.92 | ALDH1A1 (0.44) | MAPTTP53POLBSMN1; SMN2GRM5 | |
| SCHEMBL15034141 | 0.92 | SMN1; SMN2 (0.46) | MAPTTP53POLBSMN1; SMN2CFTR | |
| SCHEMBL15034162 | 0.91 | CYP3A4 (0.45) | MAPTTP53SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL15034134 | 0.90 | CFTR (0.44) | MAPTTP53POLBSMN1; SMN2CFTR | |
| SCHEMBL15034186 | 0.90 | MAPT (0.43) | MAPTTP53POLBSMN1; SMN2GRM5 | |
| SCHEMBL15034135 | 0.89 | MAPT (0.49) | MAPTTP53POLBSMN1; SMN2CFTR | |
| SCHEMBL15019972 | 0.88 | SLC6A7 (0.43) | SMN1; SMN2GRM5SLC6A7ALDH1A1HPGD | |
| SCHEMBL15034168 | 0.88 | MAPT (0.41) | MAPTTP53POLBSMN1; SMN2 | |
| SCHEMBL15034094 | 0.86 | SLC6A7 (0.42) | MAPTTP53POLBSMN1; SMN2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883789-B2 | Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-11 | — | — | US | disclosed |
| US-8883789-B2 | Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-11 | — | — | US | disclosed |
| US-20130158042-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158042-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158042-A1 | NOVEL COMPOUNDS | GRM5, GRIK5, GRM1 | MAPT 270/4885TP53 3722/4885POLB 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.